Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + tacabrutideg + rituximab in Waldenström macroglobulinemia
ACTRN12626000174381Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of sonrotoclax, tacabrutideg and rituximab in Waldenström macroglobulinemia (WM), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Very Good Partial Response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sonrotoclaxtacabrutidegrituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on ACTRN12626000174381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000174381.